JAK Inhibitor denied as non-formulary by Cigna?

Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies JAK Inhibitors as Non-Formulary — and Why You Can Appeal

A non-formulary denial means the specific JAK inhibitor your prescriber selected is not included on Cigna's drug formulary for your plan tier, or is placed at a tier that your benefit does not cover without special authorization. This is one of the most procedurally straightforward denials to challenge, because the appeal path is well-defined and the clinical case for formulary exception is often strong.

## Why This Denial Happens

Cigna's formulary places drugs into tiers based on cost, contract negotiations, and therapeutic alternatives. A JAK inhibitor may be non-formulary because a competitor within the same drug class holds a preferred position, or because the formulary was not updated to reflect current clinical guidelines. Non-formulary status does not mean the drug is inappropriate — it means it was not on the pre-approved list.

## Your Appeal Rights

• Formulary Exception / Medical-Necessity Override: nearly all plans, including Cigna, have a formal formulary-exception process. You are entitled to request this in writing.
• ERISA §503: applies to employer-sponsored plans; requires full-and-fair review.
• ACA §2719 External Review: available after internal appeals are exhausted. The external-review window is typically approximately four months from a final adverse determination — confirm the exact date on your denial letter. Expedited external review is available when clinically urgent.

## Concrete Appeal Process

1. Request a formulary exception simultaneously with (or before) filing an internal appeal — the two processes can run in parallel. 2. File the internal appeal within the timeframe on your denial letter. 3. If denied, escalate to external review without delay.

## Documentation to Gather

• Clinical rationale for the non-formulary agent: a prescriber letter explaining why the specific JAK inhibitor chosen (rather than a formulary alternative) is medically necessary. This should address any formulary alternatives Cigna might prefer and explain why they are unsuitable for this patient (prior failure, intolerance, contraindication, or a clinically meaningful difference).
• Prior-treatment history: dated records of every formulary alternative already tried, showing outcomes.
• Diagnosis and severity documentation: specialist notes and objective disease measures.
• FDA prescribing label reference: the prescriber's letter should reference the approved indications in the product label for the prescribed drug.

## Criteria-Mapping Structure

Pull Cigna's published formulary-exception criteria (available in the plan documents or by request). Alongside them, obtain the FDA-approved prescribing information for the specific JAK inhibitor. Create a side-by-side mapping: each exception criterion on the left, the chart evidence satisfying it on the right. Pay particular attention to any requirement that formulary alternatives were tried and failed — document each with dates and documented outcomes.